Galapagos Cystic Fibrosis Drug Trails Vertex's 'Mega-Franchise': RBC

Vertex Pharmaceuticals (VRTX) remains ahead of Galapagos (GLPG) in developing a triple of drugs to treat cystic fibrosis, RBC analyst Michael Yee said Thursday after Galapagos unveiled positive phase 2 data for its first CF pill.

Galapagos' GLPG-1837 lowered FEV1 "in-line" with data from Vertex's Kalydeco. FEV1 is a ratio used in the diagnosis of obstructive and restrictive lung disease. GLPG-1837 and Kalydeco belong to a class of drugs called potentiators.

But developing a triple is no...

What feeling does this article give you?

#hashtags to follow:

Vertex Pharmaceuticals [+]    VRTX [+]    Galapagos [+]    GLPG [+]    RBC [+]    Michael Yee [+]    Kalydeco [+]   

More #news: